Subject(s)
Mediastinal Neoplasms/diagnostic imaging , Mediastinal Neoplasms/surgery , Thoracic Surgery, Video-Assisted , Abdomen , Aged , Female , Humans , Male , ThoraxSubject(s)
Diaphragm/abnormalities , Pneumothorax/etiology , Adult , Coitus , Diagnosis, Differential , Drainage , Endometriosis/diagnosis , Female , Humans , Menstruation , Pleurodesis , Pneumothorax/surgery , Recurrence , ThoracoscopyABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Thoracic Surgery, Video-Assisted , Vascular Neoplasms/surgery , Aorta, Abdominal/pathology , Aorta, Thoracic/pathologyABSTRACT
INTRODUCTION: In the scientific literature, contradictory results has been published on the prognostic value of the loss of expression of blood group antigen A (BAA) in lung cancer. The objective of our study was to analyze this fact in our surgical series. PATIENTS AND METHODS: In a multicenter study, 402 non-small-cell lung cancer (NSCLC) patients were included. All were classified as stage-I according to the last 2009-TNM classification. We analyzed the prognostic influence of the loss of expression of BAA in the 209 patients expressing blood group A or AB. RESULTS: The 5-year cumulative survival was 73% for patients expressing BAA vs 53% for patients with loss of expression (P=.03). When patients were grouped into stages IA and IB, statistical significance was only observed in stage I-A (P=.038). When we analyzed the survival according to histologic type, those patients with adenocarcinoma and loss of expression of BAA had a lower survival rate that was statistically very significant (P=.003). The multivariate analysis showed that age, gender and expression of BAA were independent prognostic factors. CONCLUSIONS: The loss of expression of blood group antigen A has a negative prognostic impact in stage I NSCLC, especially in patients with adenocarcinoma.
Subject(s)
ABO Blood-Group System/metabolism , Antigens, Neoplasm/metabolism , Carcinoma, Non-Small-Cell Lung/enzymology , Chromosome Deletion , Chromosomes, Human, Pair 9/genetics , DNA Methylation , Gene Deletion , Lung Neoplasms/enzymology , N-Acetylgalactosaminyltransferases/deficiency , Neoplasm Proteins/deficiency , Adenocarcinoma/chemistry , Adenocarcinoma/enzymology , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/chemistry , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Female , Humans , Immunoenzyme Techniques , Lung Neoplasms/chemistry , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Middle Aged , N-Acetylgalactosaminyltransferases/genetics , N-Acetylgalactosaminyltransferases/metabolism , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Neoplasm Staging , Pneumonectomy , Prognosis , Retrospective StudiesABSTRACT
INTRODUCTION: The new 2009 TNM classification introduced important modifications in lung cancer staging. The aim of this study is to validate our series of patients with pathologic stage I non-small-cell lung cancer according to the 7th edition of the TNM classification of malignant tumors and to the factors related with prognosis. PATIENTS AND METHODS: A multicenter retrospective study was performed. Survival rates were calculated by the Kaplan-Meier method, and for multivariate analyses, Cox proportional hazards regression model was used. The following variables were analyzed: age, sex, pathologic stage, T category, histology, type of resection and tumor size. RESULTS: A total of 402 patients were included. Mean follow-up was 70.18 months. Overall 5-year survival was 68%. Males and patients over 70 had lower survival. Prognosis worsened with increasing pathologic stage, T category and tumor size. We found no statistically significant differences in prognosis for histology or type of resection. Multivariate analysis showed age, sex and pathologic stage to be independent prognostic factors. CONCLUSIONS: Survival results and the analysis of prognostic factors in our series are similar to those published in the new 2009 TNM classification. The most important prognostic factor is pathologic stage. Other adverse prognostic factors include male sex and age over 70.
Subject(s)
Carcinoma, Non-Small-Cell Lung/mortality , Lung Neoplasms/mortality , Aged , Carcinoma, Non-Small-Cell Lung/pathology , Female , Humans , Lung Neoplasms/pathology , Male , Neoplasm Staging , Prognosis , Retrospective Studies , Survival RateABSTRACT
Introducción: La nueva clasificación TNM de 2009 ha introducido importantes modificaciones en la estadificacióndel cáncer de pulmón. El objetivo de este trabajo es validar nuestra serie de pacientes concarcinoma no microcítico de pulmón en estadio I patológico según la séptima edición de la clasificaciónTNM de los tumores malignos y analizar los factores relacionados con el pronóstico.Pacientes y métodos: Se realizó un estudio retrospectivo y multicéntrico. Para el análisis de supervivenciase utilizó el método de Kaplan-Meier y para el análisis multivariable, la regresión de Cox. Se analizaronlas siguientes variables: edad, sexo, estadio patológico, categoría T, tipo histológico, tipo de resección ytamaño tumoral.Resultados: Se incluyó a 402 pacientes con un seguimiento medio de 70,18 meses. La supervivencia globala los 5 años fue del 68%. Los varones y los pacientes mayores de 70 años tenían una menor supervivencia.El pronóstico empeoraba a medida que aumentaba el estadio patológico, la categoría T y el tamañotumoral. No encontramos diferencias pronósticas estadísticamente significativas en relación con el tipohistológico y el tipo de resección practicada. El análisis multivariable mostró que la edad, el sexo y elestadio patológico son factores pronósticos independientes.Conclusiones: Los resultados de supervivencia y el análisis de factores pronósticos de nuestra serie seajustan a los publicados en la nueva clasificación TNM de 2009. El factor pronóstico más importante esel estadio patológico. Otros factores pronósticos desfavorables son el sexo masculino y la edad mayor de70 años (AU)
Introduction: The new 2009 TNM classification introduced important modifications in lung cancer staging. The aim of this study is to validate our series of patients with pathologic stage I non-small-cell lung canceraccording to the 7th edition of the TNM classification of malignant tumors and to the factors related withprognosis.Patients and methods: A multicenter retrospective study was performed. Survival rates were calculated by the Kaplan-Meier method, and for multivariate analyses, Cox proportional hazards regression model was used. The following variables were analyzed: age, sex, pathologic stage, T category, histology, type of resection and tumor size. Results: A total of 402 patients were included. Mean follow-up was 70.18 months. Overall 5-year survivalwas 68%. Males and patients over 70 had lower survival. Prognosis worsened with increasing pathologicstage, T category and tumor size. We found no statistically significant differences in prognosis for histologyor type of resection. Multivariate analysis showed age, sex and pathologic stage to be independentprognostic factors.Conclusions: Survival results and the analysis of prognostic factors in our series are similar to those publishedin the new 2009 TNM classification. The most important prognostic factor is pathologic stage. Otheradverse prognostic factors include male sex and age over 70 (AU)
Subject(s)
Humans , Male , Female , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Survival Analysis , Prognosis , Carcinoma, Non-Small-Cell Lung/surgery , Carcinoma, Non-Small-Cell Lung/epidemiologyABSTRACT
No disponible
No disponible
Subject(s)
Humans , Female , Adult , Pneumothorax/diagnosis , Pneumothorax/therapy , Thoracoscopy , Biopsy/instrumentation , Biopsy/methods , Pneumothorax , DiaphragmABSTRACT
No disponible
No disponible